范科米辛诱导的免疫血液溶解性贫血 - 一个病例报告和文献综述
Yilin Song1,2, Meher Ali1, Rukhsar Shaikh3
1Department of Internal Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD, USA.
概括
药物诱导的免疫血液溶解性贫血 (DIIHA) 是一种罕见的疾病. 这一案例突出了万科米辛作为DIIHA的不常见原因,强调了临床意识和及时诊断的必要性.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 药物诱导的免疫血液溶解性贫血 (DIIHA) 是一种罕见但严重的药物并发症.
- 虽然类素是常见的罪祸首,但其他抗生素也可能导致DIIHA.
- 由于潜在的致命后果,迅速识别和管理至关重要.
研究的目的:
- 报告一个具有挑战性的万科米辛诱导免疫血液溶解性贫血病 (DIIHA) 病例.
- 提高人们对万科米辛作为DIIHA的不常见原因的认识.
- 总结关于万科米辛诱导的血液溶解性贫血的现有文献.
主要方法:
- 一个患者的病例介绍,疑似患有万科素诱导的血液溶解性贫血.
- 诊断工作包括血清学确认.
- 文献审查报告的万科素诱导的DIIHA病例.
主要成果:
- 患者呈现出与血液溶解一致的血红蛋白快速下降.
- 诊断在放弃万科米辛后在血清学上得到证实.
- 一项文献审查发现了四个先前报告的万科素诱导的DIIHA.病例.
结论:
- 范科米辛是一种不常见但重要的药物诱导免疫血液溶解性贫血的原因.
- 早期识别和停止使用万科米辛是成功管理的关键.
- 需要提高临床意识,以改善诊断和患者的治疗结果.
相关概念视频
Hypersensitivity Reactions: Cytolytic Reactions
78
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
78
Drug Toxicity: Allergic Reactions
80
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
80
Acute Kidney Injury IV: Diagnostic Studies and Prevention
419
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
419
Blood Transfusion and Agglutination
15.2K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.2K
Drug toxicity: Idiosyncratic Reactions
75
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
75
Drug Toxicity: Risk factors
66
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
66


